PeptiSystems AB Signs Distributorship Agreement with Gene Company Limited to Expand Peptide and Oligonucleotide Synthesizers Distribution in China, Hong Kong, and Macau

6th of November, 2024 - Uppsala, Sweden,

​

PeptiSystems AB, a leading innovator in flowthrough peptide and oligonucleotide synthesis technology, is pleased to announce a new distribution agreement with Gene Company Limited, a well-established life sciences and biotechnology distributor in China. Through this partnership, Gene will become the distributor of PeptiSystems’ new-generation peptide and oligonucleotide synthesizers in China, Hong Kong, and Macau.

​

This strategic partnership is a significant step for PeptiSystems as it expands its footprint in the rapidly growing pharma, biotech, and CDMO markets in Greater China. By partnering with Gene, PeptiSystems will leverage Gene extensive regional network and market expertise to deliver innovative peptide and oligonucleotide synthesis technology to industry professionals across this dynamic region.

​

“We are excited to join forces with Gene, a respected distributor with a strong presence from 30 years of doing business in the Greater China region,” said Karin Granath, CEO of PeptiSystems. “Our agreement with Gene will ensure that more customers have access to our best-in-class peptide and oligonucleotide synthesizers, furthering our mission to support PeptiSystems’ transformational flow through technology and strategic expansion in this fast-growing market.”

​

“It is our pleasure to work with PeptiSystems, which is one of the important pioneer and expert in the field of Oligonucleotide and Peptide synthesis”, said Idy Leung, Business Support Manager of Gene Company. “We wish our collaboration will provide great opportunities and development on Oligonucleotide and Peptide manufacturing, especially in pharmaceutical and related fields in the Greater China region”.

​

About PeptiSystems AB

PeptiSystems, based in Uppsala, Sweden, develops instruments for process development and manufacturing of peptide and oligonucleotide therapeutics based on flow-through column technology. Utilizing the solid-phase synthesis approach, the instruments are designed to reduce solvent consumption, improve synthesis control, and reduce synthesis time while maintaining equal or higher purity and yield compared to what is obtained with current technologies. This new generation of synthesis instruments provides a higher degree of automation and a greener manufacturing process.

For more information, please contact Karin Granath, CEO of PeptiSystems at karin.granath@peptisystems.com or visit our website at www.peptisystems.com.

​

About Gene Company Limited

Gene Company Limited (hereinafter referred to as “Gene”) is a sales & distribution company under GeneTech (Shanghai), established in Hong Kong since 1992. Gene are one of the most professional service and key research product providers for life science and biotech industry in China market. After 30 years focusing on professional operations with holding a good market value and reputation, Gene are now representing for more than 70 renowned global partners in the fields like academic, institutes; biotech, pharmaceutical research; hospitals, agriculture & environmental, government department etc. Currently Gene's serving networks covers China markets with more than 650 headcounts, including 400+ sales, marketing specialists, application scientists and professionals in the distribution of capital instruments, general instruments, reagents & consumables and others. In China, Gene's distribution network covers more than 20 major cities, including top-tier cities and special administrative regions like Beijing, Shanghai, Guangzhou, Hong Kong, and Macau.

For more information, please contact Idy Leung, Business Support Manager: idy_leung@genehk.com or visit our website at https://www.genehk.com